Breaking News Instant updates and real-time market news.

UNG

United States Natural Gas Fund

$37.06

-0.7 (-1.85%)

, RACE

Ferrari

$109.22

0.9 (0.83%)

08:45
11/30/18
11/30
08:45
11/30/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: UNG (UNG) 3.22% +0.33, Ferrari (RACE) 0.59% +0.13, FAS (FAS) 0.70% +0.12, Invesco QQQ ETF (QQQ) 0.61% +0.08, Euro ETF (FXE) 1.58% +0.07, Novartis (NVS) 0.47% +0.06, Deutsche Bank (DB) 0.42% +0.02, AVEO Oncology (AVEO) 6.50% +0.02, Ebix (EBIX) 0.83% +0.02, and Intelsat (I) 0.88% +0.01.

UNG

United States Natural Gas Fund

$37.06

-0.7 (-1.85%)

RACE

Ferrari

$109.22

0.9 (0.83%)

QQQ

Invesco QQQ Trust

$168.14

-0.52 (-0.31%)

FXE

Euro Currency Trust

$108.94

0.23 (0.21%)

NVS

Novartis

$91.02

1.27 (1.42%)

DB

Deutsche Bank

$9.42

-0.47 (-4.75%)

AVEO

Aveo Pharmaceuticals

$2.00

-0.06 (-2.91%)

EBIX

Ebix

$47.04

37.665 (401.76%)

I

Intelsat

$26.30

-2.85 (-9.78%)

  • 30

    Nov

  • 30

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

  • 30

    Nov

UNG United States Natural Gas Fund
$37.06

-0.7 (-1.85%)

RACE Ferrari
$109.22

0.9 (0.83%)

10/16/18
BOFA
10/16/18
NO CHANGE
BOFA
Ferrari, PayPal added to US 1 List, ADP, NetApp removed at BofA/Merrill
10/11/18
10/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Huntington Ingalls (HII) downgraded to Sell from Neutral at Goldman Sachs with analyst Noah Poponak saying the company's pace of growth may not support current valuation levels. 2. Ferrari (RACE) downgraded to Hold from Buy at Jefferies with analyst Philippe Jean Houchois saying he re-based his expectations lower to reflect higher upfront investments and a lower quality of earnings as management's new strategy of less volume and more exclusivity takes hold. 3. Valero (VLO) downgraded to Hold from Buy at Tudor Pickering. 4. TransDigm (TDG) downgraded to Neutral from Outperform at Baird with analyst Peter Arment saying the Esterline (ESL) deal is a shift in the company's strategy in buying a "fixer-up asset" with significantly below average returns that will take time to improve. He believes it will be an overhang on the stock near-term. Arment maintained his $365 price target on TransDigm shares. 5. Tata Motors (TTM) downgraded to Hold from Buy at HSBC with analyst Amyn Pirani saying while the company's India business has surprised positively, Jaguar Land Rover's volumes have continued to decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/18
JEFF
10/11/18
DOWNGRADE
Target $132
JEFF
Hold
Ferrari downgraded to Hold from Buy at Jefferies
Jefferies analyst Philippe Jean Houchois downgraded Ferrari to Hold and lowered his price target for the shares to $132 from $155. The analyst re-based his expectations lower to reflect higher upfront investments and a lower quality of earnings as management's new strategy of less volume and more exclusivity takes hold.
10/10/18
10/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Discovery (DISCA) upgraded to Outperform from Neutral at Credit Suisse with analyst Doug Mitchelson saying he has reviewed the company's Nielsen ratings trends in detail, discussed the company's ad execution with industry contacts and recalibrated distribution trends leading to an increase in his U.S. revenue forecast and increased confidence in his above-Street EBITDA estimates. 2. McDonald's (MCD) upgraded to Buy from Neutral at Guggenheim. 3. Ferrari (RACE) upgraded to Hold from Sell at Societe Generale with analyst Stephen Reitman saying the final version of the mid-term FY22 plan shared by new CEO Louis Camilleri in September broadly repeats the key financial goals first stated in February, but the manner as to how these will be achieved appears to have fundamentally altered. 4. Intuitive Surgical (ISRG) upgraded to Overweight from Neutral at Piper Jaffray with analyst JP McKim saying a survey of doctors from various specialties came back favorable for robotics and confirms that robotic surgery penetration is going "much higher." 5. Tile Shop (TTS) assumed with a Buy from Neutral at Citi with analyst Geoffrey Small saying the hard-surface flooring sector is attractive given its favorable growth profile, highly-fragmented structure and because it carries very little threat of e-commerce disruption. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
QQQ Invesco QQQ Trust
$168.14

-0.52 (-0.31%)

11/05/18
BOFA
11/05/18
NO CHANGE
BOFA
Invesco QQQ downgraded to Less Attractive from More Attractive at BofA/Merrill
BofA/Merrill ETF Strategist Mary Ann Bartels downgraded the Invesco QQQ Trust to Less Attractive from Most Attractive citing large exposure to Apple (AAPL) and Friday's downgrade by analyst Wamsi Mohan to Neutral from Buy, combined with the fund's deteriorating price momentum.
FXE Euro Currency Trust
$108.94

0.23 (0.21%)

NVS Novartis
$91.02

1.27 (1.42%)

11/19/18
GSCO
11/19/18
UPGRADE
GSCO
Conviction Buy
Novartis upgraded to Conviction Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Katherine Alexakis Friday evening upgraded Novartis to Buy from Neutral and added the shares to her firm's Conviction List. The analyst believes Novartis is entering a period of sustained sales growth, driven by a "reinvigorated" pharma business, recently launched products and late-stage pipeline assets. Alexakis sees a "more focused company with higher returns and growth, meriting a premium valuation to large-cap EU pharma."
11/26/18
COWN
11/26/18
UPGRADE
COWN
Outperform
Novartis upgraded to Outperform from Market Perform at Cowen
11/26/18
COWN
11/26/18
UPGRADE
Target $100
COWN
Outperform
Cowen upgrades Novartis to Outperform, calls stock a best idea for 2019
As reported previously, Cowen analyst Steven Scala upgraded Novartis to Outperform from Market Perform. The analyst called it his Best Idea for 2019 as the company has transformed its business to deliver big potential new drugs with upside potential. He also cites aggressive management and the recent underperformance of the shares. Scala raised his price target to $100 from $90 on Novartis shares.
11/26/18
11/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Neutral from Sell at MoffettNathanson analyst Craig Moffett citing valuation. 2. Cognizant (CTSH) upgraded to Buy from Neutral at Goldman Sachs with analyst James Schneider saying Improving revenue growth brings prospects for a stock "re-rating." 3. Regions Financial (RF) upgraded to Overweight from Neutral at JPMorgan with analyst Vivek Juneja saying he expects the company to benefit from commercial and industrial loan growth, low deposit beta and improved efficiency. 4. Intuit (INTU) upgraded to Outperform from Sector Perform at RBC Capital with analyst Ross MacMillan citing the findings from his most recent survey of tax filers which suggests that "do-it-yourself" tax preparation should gain share from assisted filings as a result of the latest tax code changes. 5. Novartis (NVS) upgraded to Outperform from Market Perform at Cowen with analyst Steven Scala saying he called it his Best Idea for 2019 as the company has transformed its business to deliver big potential new drugs with upside potential. He also cites aggressive management and the recent underperformance of the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DB Deutsche Bank
$9.42

-0.47 (-4.75%)

08/13/18
BOFA
08/13/18
DOWNGRADE
Target $9
BOFA
Underperform
Deutsche Bank downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Andrew Stimpson downgraded Deutsche Bank to Underperform from Neutral saying he expects the earnings downgrade cycle to continue given CIB revenue headwinds.
08/10/18
08/10/18
DOWNGRADE

Underweight
Morgan Stanley cuts Deutsche Bank to Underweight on limited top-line visibility
As previously reported, Morgan Stanley analyst Magdalena Stoklosa downgraded Deutsche Bank to Underweight from Equal Weight, stating that while she gives management "full credit" for its cost cutting efforts, it is hard to have any visibility on the top line. She assumes 2018-20 revenue CAGR of just 1.5%, which is below the average for Eurozone banks and below managements target of 4%. While recognizing the risk of downgrading Deutsche Bank "at the bottom," Stoklosa sees current conditions as unlikely to be conducive to a near-term re-rating, she tells investors. She has an EUR9 target on the bank's shares.
08/10/18
MSCO
08/10/18
DOWNGRADE
MSCO
Underweight
Deutsche Bank downgraded to Underweight from Equal Weight at Morgan Stanley
06/01/18
RBCM
06/01/18
DOWNGRADE
RBCM
Underperform
Deutsche Bank downgraded to Underperform from Sector Perform at RBC Capital
AVEO Aveo Pharmaceuticals
$2.00

-0.06 (-2.91%)

11/06/18
HCWC
11/06/18
NO CHANGE
Target $9
HCWC
Buy
Aveo Pharmaceuticals price target raised to $9 from $6.50 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Aveo Pharmaceuticals to $9 saying the company announced positive topline results from the Phase 3 TIVO-3 study investigating the use of tivozanib for the treatment of refractory renal cell carcinoma. The analyst views the results as "very promising" and believes tivozanib still has "ample opportunity" to show a superior overall survival benefit. He believes the drug is on track for approval in 2020 and keeps a Buy rating on Aveo Pharmaceuticals.
11/06/18
NATL
11/06/18
DOWNGRADE
NATL
Neutral
Aveo Pharmaceuticals downgraded to Neutral from Buy at National Securities
11/15/18
PIPR
11/15/18
NO CHANGE
Target $5
PIPR
Overweight
Piper Jaffray sees FDA approval of Aveo's tivozanib in 2020
After Aveo Pharmaceuticals announced European partner EUSA is now receiving German reimbursement for tivozanib to treat first-line advanced renal cell carcinoma, Piper Jaffray analyst Edward Tenthoff said he forecasts royalties of $525,000 this year and $3M in 2019. Tenthoff also forecasts FDA approval and a U.S. launch for tivozanib in 2020, projecting initial sales of $32M growing to $218M by 2025. He maintains an Overweight rating and $5 price target on Aveo shares.
11/27/18
HCWC
11/27/18
NO CHANGE
HCWC
Buy
ImmunoGen CFO resignation not based on current role, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay says the resignation of ImmunoGen (IMGN) CFO David Johnston after the executive was found guilty for civil securities fraud has little to do with the execution of his current responsibilities, but a reflection of his tenure with Aveo Pharmaceuticals (AVEO) pharmaceuticals between 2007 and 2012. Given that a potential guilty verdict was always a possibility, the analyst anticipates a potential replacement "in the not so distant future." With ImmunoGen having made "significant strides" over the past five years, and now closer to commercialization with mirvetuximab Phase 3 readout anticipated during the first half of 2019, any potential replacement might come with prior oncology commercialization experience, and might be a better fit with future needs of the company, Chattopadhyay tells investors in a research note titled "Water Under the old AVEO Bridge." He admits, however, that the resignation is publicity ImmunoGen "could have done without." Chattopadhyay keeps a Buy rating on ImmunoGen with an $18 price target.
EBIX Ebix
$47.04

37.665 (401.76%)

09/26/18
BMOC
09/26/18
INITIATION
Target $85
BMOC
Market Perform
Ebix initiated with a Market Perform at BMO Capital
As reported earlier, BMO Capital analyst James Fotheringham initiated Ebix with a Market Perform rating and a price target of $85. The analyst says the company's valuation appears "full" and its business model offers "below-average potential to surprise positively with respect to revenue growth". If it does grow above expectations, Fotheringham states the upside would most likely come from the company's "potential to continue to grow by acquisition, as well as by its exposure to fast-growing international markets" like India and Brazil.
10/08/18
CHLM
10/08/18
NO CHANGE
Target $110
CHLM
Buy
Ebix share drop a buying opportunity, says Craig-Hallum
Noting that the company has announced that it will be changing auditors, Craig-Hallum analyst Jeff Van Rhee says his opinion on Ebix is unchanged. While a negative reaction to the auditor change headline is to be expected, the magnitude of the reaction appears to be misguided, he contends. The analyst points out that there is no difference of opinion on numbers, the company appears to be seeking and on a path to a "Big Four" auditor, and a second half of 2019 IPO timeline for EbixCash appears to be intact. He reiterates a Buy rating and $110 price target on the shares.
10/08/18
MAXM
10/08/18
NO CHANGE
Target $113
MAXM
Buy
Ebix pullback on auditor change overreaction a buying opportunity, says Maxim
Maxim analyst Allen Klee thinks the market is overreacting to Ebix's announcement that it will be changing auditors, noting that his understanding is that the company is required to use an Indian auditor given that India has become a majority of its revenue. He also noted that the company said it plans to engage a "Big 4" auditor for all operations in 2019. He sees the pullback on the auditor change news creating a "compelling" buying opportunity and keeps a Buy rating and $113 price target on Ebix shares, which are down 13% to $62.72 in early afternoon trading.
09/26/18
BMOC
09/26/18
INITIATION
Target $85
BMOC
Market Perform
Ebix initiated with a Market Perform at BMO Capital
BMO Capital started Ebix with a Market Perform rating and $85 price target.
I Intelsat
$26.30

-2.85 (-9.78%)

06/20/18
06/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Citi (C) upgraded to Buy from Hold at Deutsche Bank. 2. BT Group (BT) upgraded to Buy from Hold at Jefferies with analyst Jeremy Dellis saying reducing the dividend to increase investment in fiber-to-the-premises networks to satisfy demands by British telecommunications regulator Ofcom could make BT a "geat deal more investable." 3. Duke Energy (DUK) upgraded to Buy from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing recent share underperformance and resolved regulatory overhangs. 4. Glatfelter (GLT) upgraded to Buy from Neutral at DA Davidson with analyst Steven Chercover saying he is "incrementally positive" on the stock based on his view of the announced acquisition of GP's European airlaid nonwoven business, which adds 35K tonnes per year in capacity to the company's existing 129K tpy. 5. Intelsat (I) upgraded to Outperform from Sector Perform at RBC Capital with analyst Wilton Fry citing his expected FCC release of the Notice of Proposed Rulemaking this week that will lead to adoption of the company's C-band proposal, "conservatively" estimating that this could add over $19 in earnings per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/18
MSCO
11/12/18
UPGRADE
MSCO
Equal Weight
Intelsat upgraded to Equal Weight from Underweight at Morgan Stanley
11/12/18
11/12/18
UPGRADE
Target $28

Equal Weight
Morgan Stanley upgrades Intelsat to Equal Weight on clearer path for C-band
As previously reported, Morgan Stanley analyst Simon Flannery upgraded Intelsat to Equal Weight from Underweight, stating that the C-band process has moved "remarkably quickly" through the regulatory process and he assumes gross proceeds of $20B from monetizing the spectrum. However, Intelsat's core satellite business continues to face secular and competitive headwinds, Flannery added in his note to investors. He raised his price target on Intelsat shares to $28 from $8.
06/20/18
RBCM
06/20/18
UPGRADE
Target $30
RBCM
Outperform
Intelsat upgraded to Outperform at RBC Capital on expected FCC NPRM draft
As reported earlier, RBC Capital analyst Wilton Fry upgraded Intelsat to Outperform from Sector Perform and raised his price target to $30 from $5. Fry cites his expected FCC release of the Notice of Proposed Rulemaking this week that will lead to adoption of the company's C-band proposal, "conservatively" estimating that this could add over $19 in earnings per share. The analyst adds that the company's recent equity and convertible debt issuance "enabled Intelsat to break the captive nature of some of its debt instruments, leaving a pathway to refinance until 2023".

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.